Trials / Completed
CompletedNCT02480101
Reactogenicity, Safety and Immunogenicity of a LAIV H7N9 Influenza Vaccine
Reactogenicity, Safety and Immunogenicity of a Live Monovalent A/17/Anhui/2013/61 (H7N9) Influenza Vaccine
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Research Institute of Influenza, Russia · Academic / Other
- Sex
- All
- Age
- 18 Years – 49 Years
- Healthy volunteers
- Accepted
Summary
This is a single centre phase I, double-blind placebo-controlled study to assess reactogenicity, safety and immunogenicity of a live monovalent A/17/Anhui/2013/61 (H7N9) influenza vaccine in healthy male and female adults, 18 through 49 years of age .
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | H7N9 live influenza vaccine | H7N9 live influenza vaccine |
| BIOLOGICAL | Placebo | Lyophilized purified allantoic fluid of chicken embryos with stabilizers |
Timeline
- Start date
- 2014-10-01
- Primary completion
- 2014-12-01
- Completion
- 2015-04-01
- First posted
- 2015-06-24
- Last updated
- 2015-06-24
Source: ClinicalTrials.gov record NCT02480101. Inclusion in this directory is not an endorsement.